StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Share-Based Compensation Expense by Year

Share-Based Compensation Expense ($M)

Novartis Share-Based Compensation Expense: $1,330M in FY2025, up 1.8% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
1,330
Period ended Dec 31, 2025
Change on a year earlier
+1.8%
1,307 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Novartis Form 20-F (0001114448-26-000004) ↗

Reported in Form 20-F Note 26.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedShare-Based Compensation Expense ($M)Year on yearSource
FY2025Dec 31, 20251,330+1.8%Novartis Form 20-F (0001114448-26-000004) ↗
FY2024Dec 31, 20241,307+14.4%Novartis Form 20-F (0001114448-26-000004) ↗
FY2023Dec 31, 20231,142+16.3%Novartis Form 20-F (0001114448-26-000004) ↗
FY2022Dec 31, 2022982+7.9%Novartis Form 20-F (0001370368-25-000004) ↗
FY2021Dec 31, 2021910-5.0%Novartis Form 20-F (0001370368-24-000004) ↗
FY2020Dec 31, 2020958-10.2%Novartis Form 20-F/A (0001370368-23-000048) ↗
FY2019Dec 31, 20191,067+16.2%Novartis Form 20-F (0001370368-22-000010) ↗
FY2018Dec 31, 2018918+7.6%Novartis Form 20-F (0001370368-21-000006) ↗
FY2017Dec 31, 2017853+0.8%Novartis Form 20-F (0001370368-20-000003) ↗
FY2016Dec 31, 2016846–Novartis Form 20-F (0001370368-19-000002) ↗

Cite this data

StockData. (2026). Novartis Share-Based Compensation Expense ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/wf-sbp-exp-total

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?